Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Hidden danger: flu patients in ICU face fungal lung threat

NCT ID NCT04530799

Knowledge-focused Sponsor: Radboud University Medical Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tracked 241 ICU patients with severe influenza to see how many developed a fungal lung infection called IAPA. Researchers collected blood and fluid samples to identify risk factors. The goal is to help doctors spot high-risk patients earlier.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could help doctors identify which flu patients in the ICU are most at risk for a serious fungal infection, leading to earlier detection and better care.
What could go wrong
This is an observational study, not a treatment trial. It only looks for patterns and cannot prove cause and effect. Results may not apply to all patients or hospitals.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

241 people

The number who actually took part.

Started

Mar 2022

Finished

May 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The target patient population is the EORTC-negative population of critically ill influenza patients at ICU. Patient identification will rely on daily review of ICU patients with respiratory virus panels ordered in the previous 24 hours.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients with a PCR-positive respiratory virus panel (RVP) result for influenza within 96 hours before or 48 hours after ICU admission. * Patients who require ICU admission for more than 24 hours for severe influenza. * Patients who have respiratory distress (respiratory rate \>= 25x/minute and paO2/fiO2 \< 300 with or without bilateral infiltrates) as the main reason for ICU admission. * Patients who do not have an EORTC host factor. * Patients who are at least 18 years of age. Exclusion Criteria: * Patients with age \< 18 years as extensive sampling is required * Expected survival on ICU admission ≤ 48h * Patients that are being treated actively with antifungal agents for invasive aspergillosis. * Patients or their legal representatives who did not sign the informed consent form

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Influenza with pneumonia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

aspergillosis fungal lung infectious disease influenza Invasive Pulmonary Aspergillosis pulmonary aspergilloma respiratory tract infectious disorder viral infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Influenza with pneumonia Pulmonary aspergillosis

Contacts and locations

Locations

  • AZ Delta

    Roeselare, Belgium

  • AZ St-Jan

    Bruges, Belgium

  • Amiens-Picardie University Hospital

    Amiens, 80054, France

  • AmsterdamUMC, locatie VUmc

    Amsterdam, 1081, Netherlands

  • Centre Hospitalier REgional Universitaire de Lille

    Lille, France

  • Henri Mondor Hopital

    Paris, France

  • Hopital Bichat

    Paris, France

  • Hopital Lariboisiere

    Paris, France

  • Hopital Pontchaillou, Centre Hospitalier Universitaire de Rennes

    Rennes, France

  • Radboudumc

    Nijmegen, Gelderland, 6525GA, Netherlands

  • UZ Leuven

    Leuven, Belgium

  • Universitair Medisch Centrum Groningen

    Groningen, Provincie Groningen, 9713, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.